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The patient with diabetes mellitus often suffers from functional abnormalities of
the gastrointestinal tract which can result in great concern clinically and also in im-
pairment of nutritional status and impact on management of the diabetes. In this
symposium on the varied gastrointestinal manifestations that are found in diabetes
mellitus, the authors attempt to present a state-of-the-art approach to the recogni-
tion and pathophysiology of the abnormalities as well as to define treatpnent
modalities.
Nearly all abnormalities can be explained by combinations ofganglionic parasym-
pathetic damage, degrees ofaxonal degeneration and myelin sheath destruction, and
an altered metabolic environment at the site ofneuromuscular interaction. Although
constipation is probably the most common intestinal manifestation of diabetic
autonomic neuropathy, it tends to be overshadowed by more prominent symp-
tomatology arising from changes in the gastrointestinal tract. Some of the more
recognized and clinically significant perturbations of the gastrointestinal tract relate
to gastric stasis, either acutely with the setting ofdiabetic ketoacidosis or to the more
chronic form occurring in the setting of a peripheral and visceral neurop-
athy-"gastroparesis diabeticorum."
Another gastrointestinal manifestation of diabetes mellitus, diarrhea, also can be
dramatic and result in a difficult management problem. The severity of the diarrhea
often leads to an investigation of malabsorption which usually results in minimal
evidence for steatorrhea but sometimes can lead to the unmasking of significant
bacterial colonization accompanying the sluggish small-bowel transit and resultant
bile acid deconjugation explaining the diarrhea. However, pathology of the pan-
creas can sometimes be diagnosed as well as co-existing celiac disease of the small
bowel.
Although diabetes may affect the function of the gut at every level, esophageal
dysfunction rarely results in clinical manifestations although manometric studies
can unmask motor abnormalities in the smooth muscle portion of the body of the
esophagus which also contribute to the increased frequency ofmonilia esophagitis in
these patients.
In an attempt to provide a broad base for this symposium, we have also addressed
the role of diabetes on the gastrointestinal tract of the pediatric patient, an infre-
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quently reviewed topic. Finally, we also discuss the role of the surgeon in jointly
managing many of the gastrointestinal diabetic complications as well as indications
for surgical intervention, particularly in the setting of cholelithiasis.
One still seems to come back to asking the question: "What is new in the treatment
ofdiabetic autonomic and visceral neuropathy?" The advent ofthe insulin pump has
been an exciting development in glucose control in the diabetic and from early
studies there has been some improvement in peripheral nerve conduction studies as
well as in renal function. Whether abnormal metabolism can be minimized or re-
versed at the motor end plate and/or nerve ending sites, awaits long-term controlled
studies but it would seem doubtful when addressing patients already at the visceral
neuropathy stage. Treatment directed at the environmental status of the motor end
plate addressing factors, such as myoinosytol and sorbitol pathways, may also hold
promising futures. The good news is that a new era has begun in gastrointestinal
smooth muscle and impacts directly on the diabetic complications. Metoclopramide
has been the key to unlocking a new generation ofdrugs referred to as "prokinetics."
By focusing on the modulating effects of both cholinergic stimulation and
neutralization of dopamine-mediated inhibition, this agent has resulted in net
stimulation of smooth muscle and coordinated gastrointestinal motor events with
resultant aboral movement of material through the gastrointestinal tract. This ex-
citing new era has resulted in greatly improved relief from some of the severely dis-
abling symptoms of diabetic involvement of the gut. These developments are dis-
cussed in the symposium.
174